We need to avoid getting caught up in hysteria. The FDA is a big octopus with tentacles in many areas. I think you will find that the cuts have zero relevance to drug approvals, much less generic ANDAs. The notion that the Trump administration is going to want to be seen to be restricting the flow of cheap drugs, is fanciful.
Ann: Acrux receives $1.73m advance on FY25 R&D Tax Incentive, page-11
Add to My Watchlist
What is My Watchlist?
